{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T22:33:13Z","timestamp":1772490793072,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>F\u00fcr die beiden humanpathogenen Mykoplasmenspezies <jats:italic>Mycoplasma pneumoniae<\/jats:italic> und <jats:italic>M.\u00a0genitalium<\/jats:italic> ergeben sich derzeit unterschiedliche Herausforderungen f\u00fcr die klinische Praxis.<\/jats:p>\n          <jats:p>\n            <jats:italic>M.\u00a0pneumoniae <\/jats:italic>ist eine h\u00e4ufige Ursache von ambulant erworbenen respiratorischen Infektionen, die zu asymptomatischen Verl\u00e4ufen, aber auch zu schweren atypischen Pneumonien f\u00fchren k\u00f6nnen. Hinzu kommen extrapulmonale Komplikationen. Seit Dezember 2023 werden in Sachsen, wo eine Meldepflicht besteht, Pr\u00e4valenzen gemessen, die die Zahlen aus den vergangenen Jahren um ein Vielfaches \u00fcbersteigen und auf die \u00fcbrigen Bundesl\u00e4nder grunds\u00e4tzlich \u00fcbertragbar sind. Die Ursache dieser Entwicklung d\u00fcrfte in einem reduzierten Kontakt mit dem Erreger w\u00e4hrend der COVID-19-Pandemie verbunden mit einer Verringerung der spezifischen Immunit\u00e4t in der Bev\u00f6lkerung liegen. Obwohl es keine gesicherten Daten zu einem Anstieg der Rate schwerer F\u00e4lle gibt, sind Diagnostik und Therapie dieser Situation anzupassen. Die Resistenzrate in Deutschland gegen\u00fcber den vorrangig eingesetzten Makroliden bleibt mit ca.\u00a03\u202f% g\u00fcnstig.<\/jats:p>\n          <jats:p>\n            <jats:italic>M.\u00a0genitalium <\/jats:italic>wird sexuell \u00fcbertragen und ist nur in einem Teil der beim Mann auftretenden Urethritisf\u00e4lle urs\u00e4chlich relevant. Der begrenzten epidemiologischen Bedeutung steht die zunehmende Resistenz gegen\u00fcber den in den Leitlinien empfohlenen Antibiotika Azithromycin und Moxifloxacin gegen\u00fcber, die in den im Konsiliarlabor in den vergangenen Jahren untersuchten Proben bei 69\u202f% bzw. 25\u202f% liegt. In Risikogruppen (z.\u202fB. bei M\u00e4nnern, die Sex mit M\u00e4nnern haben), in denen <jats:italic>M.\u00a0genitalium<\/jats:italic> relativ h\u00e4ufig nachzuweisen ist, muss mit noch h\u00f6heren Raten gerechnet werden. Ein Therapieerfolg ist unter diesen Bedingungen nur mit einem resistenzgeleiteten Behandlungskonzept zu erwarten.<\/jats:p>\n          <jats:p>Die vorliegende \u00dcbersicht fasst den momentanen Kenntnisstand zu beiden Erregern zusammen.<\/jats:p>","DOI":"10.1007\/s00103-025-04052-2","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T13:59:09Z","timestamp":1747058349000},"page":"932-939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Infektionen mit den humanpathogenen Mykoplasmenspezies M.\u00a0genitalium und M.\u00a0pneumoniae","Infections with the human pathogenic Mycoplasma species M.\u00a0genitalium and M.\u00a0pneumoniae"],"prefix":"10.1007","volume":"68","author":[{"given":"Roger","family":"Dumke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"4052_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1128\/CMR.00114-16","volume":"30","author":"KB Waites","year":"2017","unstructured":"Waites\u00a0KB, Xiao\u00a0L, Liu\u00a0Y et\u00a0al (2017) Mycoplasma pneumoniae from the respiratory tract and beyond. Clin Microbiol Rev 30:747\u2013809","journal-title":"Clin Microbiol Rev"},{"key":"4052_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3389\/fmicb.2020.00685","volume":"11","author":"C Bl\u00f6tz","year":"2020","unstructured":"Bl\u00f6tz\u00a0C, Singh\u00a0N, Dumke\u00a0R et\u00a0al (2020) Characterization of an immunoglobulin binding protein (IbpM) from Mycoplasma pneumoniae. Front Microbiol 11:685","journal-title":"Front Microbiol"},{"key":"4052_CR3","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/S0140-6736(13)62503-9","volume":"382","author":"P Nguipdop-Djomo","year":"2013","unstructured":"Nguipdop-Djomo\u00a0P, Fine\u00a0PEM, Halsby\u00a0KD et\u00a0al (2013) Cyclic epidemics of Mycoplasma pneumoniae infections in England and Wales from 1975 to 2009: time-series analysis and mathematical modelling. Lancet 382:S78","journal-title":"Lancet"},{"issue":"3","key":"4052_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s15010-019-01273-x","volume":"47","author":"S Hagel","year":"2019","unstructured":"Hagel\u00a0S, Schmitt\u00a0S, Kesselmeier\u00a0M et\u00a0al (2019) M.\u00a0pneumoniae and C.\u00a0pneumoniae are no relevant pathogens in critically ill patients with hospital-acquired respiratory tract infections. Infection 47(3):471\u2013474","journal-title":"Infection"},{"issue":"8","key":"4052_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.cmi.2016.05.028","volume":"22","author":"T Khoury","year":"2016","unstructured":"Khoury\u00a0T, Sviri\u00a0S, Rmeileh\u00a0AA et\u00a0al (2016) Increased rates of intensive care unit admission in patients with Mycoplasma pneumoniae: a\u00a0retrospective study. Clin Microbiol Infect 22(8):711\u2013714","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"4052_CR6","doi-asserted-by":"publisher","first-page":"e066721","DOI":"10.1136\/bmjopen-2022-066721","volume":"13","author":"S Wang","year":"2023","unstructured":"Wang\u00a0S, Tang\u00a0J, Tan\u00a0Y et\u00a0al (2023) Prevalence of atypical pathogens in patients with severe pneumonia: a\u00a0systematic review and meta-analysis. Bmj Open 13(4):e66721","journal-title":"Bmj Open"},{"key":"4052_CR7","volume-title":"Praktische Krankenhaushygiene und Umweltschutz. Springer Reference Medizin","author":"HM Just","year":"2018","unstructured":"Just\u00a0HM, Ziegler\u00a0R (2018) Isolierungsma\u00dfnahmen. In: Dettenkofer\u00a0M, al (Hrsg) Praktische Krankenhaushygiene und Umweltschutz. Springer Reference Medizin"},{"key":"4052_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fmicb.2016.00023","volume":"7","author":"M Narita","year":"2016","unstructured":"Narita\u00a0M (2016) Classification of extrapulmonary manifestations due to Mycoplasma pneumoniae infection on the basis of possible pathogenesis. Front Microbiol 7:23","journal-title":"Front Microbiol"},{"key":"4052_CR9","doi-asserted-by":"publisher","first-page":"904494","DOI":"10.3389\/fmicb.2022.904494","volume":"13","author":"R Dumke","year":"2022","unstructured":"Dumke\u00a0R (2022) Molecular tools for typing Mycoplasma pneumoniae and Mycoplasma genitalium. Front Microbiol 13:904494","journal-title":"Front Microbiol"},{"issue":"5","key":"4052_CR10","doi-asserted-by":"publisher","first-page":"e1001444","DOI":"10.1371\/journal.pmed.1001444","volume":"10","author":"EB Spuesens","year":"2013","unstructured":"Spuesens\u00a0EB, Fraaij\u00a0PL, Visser\u00a0EG et\u00a0al (2013) Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med 10(5):e1001444","journal-title":"PLoS Med"},{"key":"4052_CR11","doi-asserted-by":"publisher","first-page":"104868","DOI":"10.1016\/j.ebiom.2023.104868","volume":"98","author":"MH Koenen","year":"2023","unstructured":"Koenen\u00a0MH, de Groot\u00a0RCA, de Steenhuijsen Piters\u00a0WAA et\u00a0al (2023) Mycoplasma pneumoniae carriage in children with recurrent respiratory tract infections is associated with a\u00a0less diverse and altered microbiota. eBioMedicine 98:104868","journal-title":"eBioMedicine"},{"key":"4052_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1471-2180-8-93","volume":"8","author":"AC Nilsson","year":"2008","unstructured":"Nilsson\u00a0AC, Bj\u00f6rkman\u00a0P, Persson\u00a0K (2008) Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a\u00a0high rate of persistent infection. BMC Microbiol 8:93","journal-title":"BMC Microbiol"},{"key":"4052_CR13","unstructured":"https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2023-DON494. Zugegriffen: 4. Nov. 2024"},{"key":"4052_CR14","doi-asserted-by":"crossref","unstructured":"Meyer Sauteur PM, Beeton ML, European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group (2024) Pneumonia outbreaks due to re-emergence of Mycoplasma pneumoniae. Lancet Microbe 5247(23):406\u2013408","DOI":"10.1016\/S2666-5247(23)00406-8"},{"issue":"2","key":"4052_CR15","doi-asserted-by":"publisher","first-page":"2300707","DOI":"10.2807\/1560-7917.ES.2024.29.2.2300707","volume":"29","author":"AC Nordholm","year":"2024","unstructured":"Nordholm\u00a0AC, S\u00f6borg\u00a0B, Jokelainen\u00a0P et\u00a0al (2024) Mycoplasma pneumoniae epidemic in Denmark, October to December, 2023. Euro Surveill 29(2):2300707","journal-title":"Euro Surveill"},{"issue":"4","key":"4052_CR16","doi-asserted-by":"publisher","first-page":"2300724","DOI":"10.2807\/1560-7917.ES.2024.29.4.2300724","volume":"29","author":"DC Bolluyt","year":"2024","unstructured":"Bolluyt\u00a0DC, Euser\u00a0SM, Souverein\u00a0D et\u00a0al (2024) Increased incidence of Mycoplasma pneumoniae infections and hospital admissions in the Netherlands, November to December 2023. Euro Surveill 29(4):2300724","journal-title":"Euro Surveill"},{"key":"4052_CR17","unstructured":"Meyer Sauteur PM, Beeton ML, European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group (2023) Mycoplasma pneumoniae: gone forever? Lancet Microbe 4(10):e763"},{"issue":"9","key":"4052_CR18","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s10096-024-04901-z","volume":"43","author":"L Tang","year":"2024","unstructured":"Tang\u00a0L, Zheng\u00a0K, Ma\u00a0L et\u00a0al (2024) Epidemiologic trends and changes in humoral immunity and lymphocyte subsets levels among hospitalized children with Mycoplasma pneumoniae infection during 2019\u20132023. Eur J Clin Microbiol Infect Dis 43(9):1837\u20131845","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4052_CR19","doi-asserted-by":"publisher","first-page":"101103","DOI":"10.1016\/j.lanepe.2024.101103","volume":"47","author":"KHS Dungu","year":"2024","unstructured":"Dungu\u00a0KHS, Holm\u00a0M, Hartling\u00a0U et\u00a0al (2024) Mycoplasma pneumoniae incidence, phenotype, and severity in children and adolescents in Denmark before, during, and after the COVID-19 pandemic: a\u00a0nationwide multicentre population-based cohort study. Lancet Reg Health Eur 47:101103","journal-title":"Lancet Reg Health Eur"},{"key":"4052_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000004545","author":"I Taborda","year":"2024","unstructured":"Taborda\u00a0I, Tome\u00a0R, Ferreira\u00a0SC et\u00a0al (2024) No increase in severity of Mycoplasma pneumoniae: insights from the postpandemic epidemic. Pediatr Infect Dis\u00a0J. https:\/\/doi.org\/10.1097\/INF.0000000000004545","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"4052_CR21","doi-asserted-by":"publisher","first-page":"2332680","DOI":"10.1080\/22221751.2024.2332680","volume":"13","author":"AD Urbieta","year":"2024","unstructured":"Urbieta\u00a0AD, Barbeito Castineiras\u00a0G, Rivero\u00a0CI et\u00a0al (2024) Mycoplasma pneumoniae at the rise not only in China: rapid increase of Mycoplasma pneumoniae cases also in Spain. Emerg Microbes Infect 13(1):2332680","journal-title":"Emerg Microbes Infect"},{"key":"4052_CR22","unstructured":"https:\/\/dgpi.de\/wp-content\/uploads\/2018\/04\/Pneumonie-erworben-KA_S2k-LL_048-013l_Mar2017.pdf. Zugegriffen: 12. Nov. 2024"},{"key":"4052_CR23","unstructured":"https:\/\/register.awmf.org\/assets\/guidelines\/020-020l_S3_Behandlung-von-erwachsenen-Patienten-mit-ambulant-erworbener-Pneumonie__2021-05.pdf. Zugegriffen: 3. Febr. 2025"},{"issue":"3","key":"4052_CR24","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1128\/AAC.49.3.1190-1193.2005","volume":"49","author":"D Gruson","year":"2005","unstructured":"Gruson\u00a0D, Pereyre\u00a0S, Renaudin\u00a0H et\u00a0al (2005) In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob Agents Chemother 49(3):1190\u20131193","journal-title":"Antimicrob Agents Chemother"},{"key":"4052_CR25","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fmicb.2016.00974","volume":"7","author":"S Pereyre","year":"2016","unstructured":"Pereyre\u00a0S, Goret\u00a0J, Bebear\u00a0C (2016) Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol 7:974","journal-title":"Front Microbiol"},{"key":"4052_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ijid.2014.07.014","volume":"29","author":"R Dumke","year":"2014","unstructured":"Dumke\u00a0R, Stolz\u00a0S, Jacobs\u00a0E et\u00a0al (2014) Molecular characterization of macrolide resistance of a\u00a0Mycoplasma pneumoniae strain that developed during therapy of a\u00a0patient with pneumonia. Int J Infect Dis 29:197","journal-title":"Int J Infect Dis"},{"issue":"3","key":"4052_CR27","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3390\/pathogens10030328","volume":"10","author":"D Hubert","year":"2021","unstructured":"Hubert\u00a0D, Dumke\u00a0R, Weichert\u00a0S et\u00a0al (2021) Emergence of macrolide-resistant Mycoplasma pneumoniae during an outbreak in a\u00a0primary school: clinical characterization of hospitalized children. Pathogens 10(3):328","journal-title":"Pathogens"},{"key":"4052_CR28","unstructured":"Waites KB, Bade DJ, Bebear C et\u00a0al (2011) Methods for antimicrobial susceptibility testing for human mycoplasmas. Clinical and Laboratory Standards Institute; Report No.: M43\u2011A; Wayne. PA"},{"issue":"3","key":"4052_CR29","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.cmi.2018.10.006","volume":"25","author":"K Wagner","year":"2019","unstructured":"Wagner\u00a0K, Imkamp\u00a0F, Pires\u00a0VP et\u00a0al (2019) Evaluation of Lightmix Mycoplasma macrolide assay for detection of macrolide-resistant Mycoplasma pneumoniae in pneumonia patients. Clin Microbiol Infect 25(3):e5\u2013383.e7","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"4052_CR30","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s00431-024-05519-1","volume":"183","author":"G Ding","year":"2024","unstructured":"Ding\u00a0G, Zhang\u00a0X, Vinturache\u00a0A et\u00a0al (2024) Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia. Eur J Pediatr 183(7):3001\u20133011","journal-title":"Eur J Pediatr"},{"issue":"5","key":"4052_CR31","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1369-5274(98)80091-X","volume":"1","author":"R Herrmann","year":"1998","unstructured":"Herrmann\u00a0R, Reiner\u00a0B (1998) Mycoplasma pneumoniae and Mycoplasma genitalium: a\u00a0comparison of two closely related bacterial species. Curr Opin Microbiol 1(5):572\u2013579","journal-title":"Curr Opin Microbiol"},{"issue":"1","key":"4052_CR32","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/21505594.2022.2095741","volume":"13","author":"W Yueyue","year":"2022","unstructured":"Yueyue\u00a0W, Feichen\u00a0X, Yixuan\u00a0X et\u00a0al (2022) Pathogenicity and virulence of Mycoplasma genitalium: unraveling Ariadne\u2019s Thread. Virulence 13(1):1161\u20131183","journal-title":"Virulence"},{"issue":"11","key":"4052_CR33","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1093\/jac\/dkac281","volume":"77","author":"R Pitt","year":"2022","unstructured":"Pitt\u00a0R, Boampong\u00a0D, Day\u00a0M et\u00a0al (2022) Challenges of in vitro propagation and antimicrobial susceptibility testing of Mycoplasma genitalium. J\u00a0Antimicrob Chemother 77(11):2901\u20132907","journal-title":"J Antimicrob Chemother"},{"key":"4052_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/sextrans-2017-053384","volume":"94","author":"L Baumann","year":"2018","unstructured":"Baumann\u00a0L, Cina\u00a0M, Egli-Gany\u00a0D et\u00a0al (2018) Prevalence of Mycoplasma genitalium in different population groups: systematic review and meta-analysis. Sex Transm Infect 94:255\u2013262","journal-title":"Sex Transm Infect"},{"key":"4052_CR35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/sextrans-2019-054310","volume":"96","author":"RL Latimer","year":"2020","unstructured":"Latimer\u00a0RL, Shilling\u00a0HS, Vodstrcil\u00a0LA et\u00a0al (2020) Prevalence of Mycoplasma genitalium by anatomical site in men who have sex with men: a\u00a0systematic review and meta-analysis. Sex Transm Infect 96:563\u2013570","journal-title":"Sex Transm Infect"},{"issue":"7","key":"4052_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","volume":"22","author":"JS Jensen","year":"2024","unstructured":"Jensen\u00a0JS, Unemo\u00a0M (2024) Antimicrobial treatment and resistance in sexually transmitted bacterial infections. Nat Rev Microbiol 22(7):435\u2013450","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"4052_CR37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/jdv.17972","volume":"36","author":"JS Jensen","year":"2022","unstructured":"Jensen\u00a0JS, Cusini\u00a0M, Gomberg\u00a0M et\u00a0al (2022) 2021 European guideline on the management of Mycoplasma genitalium infections. J\u00a0Eur Acad Dermatol Venereol 36(5):641\u2013650","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4052_CR38","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1473-3099(18)30506-1","volume":"18","author":"T Kirby","year":"2018","unstructured":"Kirby\u00a0T (2018) Mycoplasma genitalium: a\u00a0potential new superbug. Lancet Infect Dis 18:951\u2013952","journal-title":"Lancet Infect Dis"},{"key":"4052_CR39","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/QAD.0b013e328323da3e","volume":"23","author":"S Napierala Mavedzenge","year":"2009","unstructured":"Napierala Mavedzenge\u00a0S, Weiss\u00a0HA (2009) Association of Mycoplasma genitalium and HIV infection: a\u00a0systematic review and meta-analysis. AIDS 23:611\u2013620","journal-title":"AIDS"},{"issue":"12","key":"4052_CR40","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1093\/cid\/ciad057","volume":"76","author":"GL Murray","year":"2023","unstructured":"Murray\u00a0GL, Plummer\u00a0EL, Bodiyabadu\u00a0K et\u00a0al (2023) gyrA mutations in Mycoplasma genitalium and their contribution to moxifloxacin failure: time for the next generation of resistance-guided therapy. Clin Infect Dis 76(12):2187\u20132195","journal-title":"Clin Infect Dis"},{"key":"4052_CR41","doi-asserted-by":"publisher","first-page":"100737","DOI":"10.1016\/j.lanepe.2023.100737","volume":"34","author":"O Mitja","year":"2023","unstructured":"Mitja\u00a0O, Suner\u00a0C, Giacani\u00a0L et\u00a0al (2023) Treatment of bacterial sexually transmitted infections in Europe: gonorrhoea, Mycoplasma genitalium, and syphilis. Lancet Reg Health Eur 34:100737","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"4052_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pathogens9010012","volume":"9","author":"R Dumke","year":"2019","unstructured":"Dumke\u00a0R, Rust\u00a0M, Glaunsinger\u00a0T (2019) MgpB types among Mycoplasma genitalium strains from men who have sex with men in Berlin, Germany, 2016\u20132018. Pathogens 9(1):12","journal-title":"Pathogens"},{"issue":"3","key":"4052_CR43","first-page":"208","volume":"99","author":"JJ Goodfellow","year":"2023","unstructured":"Goodfellow\u00a0JJ, Hughes\u00a0S, Smith\u00a0J et\u00a0al (2023) Novel use of oral chloramphenicol for treatment-resistant Mycoplasma genitalium. Sex Transm Infect 99(3):208\u2013210","journal-title":"Sex Transm Infect"},{"issue":"3","key":"4052_CR44","doi-asserted-by":"publisher","first-page":"e0079021","DOI":"10.1128\/jcm.00790-21","volume":"61","author":"KB Waites","year":"2023","unstructured":"Waites\u00a0KB, Crabb\u00a0DM, Ratliff\u00a0AE et\u00a0al (2023) Latest advances in laboratory detection of Mycoplasma genitalium. J\u00a0Clin Microbiol 61(3):e79021","journal-title":"J Clin Microbiol"},{"issue":"3","key":"4052_CR45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1473-3099(18)30080-X","volume":"18","author":"CS Bradshaw","year":"2018","unstructured":"Bradshaw\u00a0CS, Horner\u00a0PJ, Jensen\u00a0JS et\u00a0al (2018) Syndromic management of STIs and the threat of untreatable Mycoplasma genitalium. Lancet Infect Dis 18(3):251\u2013252","journal-title":"Lancet Infect Dis"},{"key":"4052_CR46","unstructured":"https:\/\/www.cdc.gov\/antimicrobial-resistance\/media\/pdfs\/2019-ar-threats-report-508.pdf. Zugegriffen: 6. Nov. 2024"},{"issue":"8","key":"4052_CR47","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/antibiotics10080962","volume":"10","author":"R Dumke","year":"2021","unstructured":"Dumke\u00a0R, Spornraft-Ragaller\u00a0P (2021) Antibiotic resistance and genotypes of Mycoplasma genitalium during a\u00a0resistance-guided treatment regime in a\u00a0German university hospital. Antibiot (basel) 10(8):962","journal-title":"Antibiot (basel)"},{"key":"4052_CR48","unstructured":"https:\/\/sti.guidelines.org.au\/sexually-transmissible-infections\/mycoplasma-genitalium\/?print=pdf. Zugegriffen: 30. Okt. 2024"},{"key":"4052_CR49","doi-asserted-by":"publisher","DOI":"10.2471\/B09104","volume-title":"Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts)","author":"World Health Organization","year":"2024","unstructured":"World Health Organization (2024) Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts). Geneva"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-025-04052-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-025-04052-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-025-04052-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:15:04Z","timestamp":1757168104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-025-04052-2"}},"subtitle":["Aktuelle epidemiologische Aspekte","Current epidemiological aspects"],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["4052"],"URL":"https:\/\/doi.org\/10.1007\/s00103-025-04052-2","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Dumke gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}